Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-18-013090
Filing Date
2018-05-11
Accepted
2018-05-10 19:19:35
Documents
50
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nvus-10q_20180331.htm 10-Q 999102
2 EX-31.1 nvus-ex311_8.htm EX-31.1 11345
3 EX-31.2 nvus-ex312_6.htm EX-31.2 11488
4 EX-32.1 nvus-ex321_9.htm EX-32.1 7487
5 EX-32.2 nvus-ex322_7.htm EX-32.2 7865
  Complete submission text file 0001564590-18-013090.txt   3505347

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT nvus-20180331.xml EX-101.INS 584363
7 XBRL TAXONOMY EXTENSION SCHEMA nvus-20180331.xsd EX-101.SCH 36509
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nvus-20180331_cal.xml EX-101.CAL 35634
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nvus-20180331_def.xml EX-101.DEF 88637
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvus-20180331_lab.xml EX-101.LAB 239907
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvus-20180331_pre.xml EX-101.PRE 182452
Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
Novus Therapeutics, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36620 | Film No.: 18824550
SIC: 2834 Pharmaceutical Preparations